[SCHEDULE 13G/A] Collegium Pharmaceutical, Inc. SEC Filing

Rhea-AI Filing Summary

The Schedule 13G/A filed for Collegium Pharmaceutical shows Principal Global Investors beneficially owns 1,466,506 shares of Collegium common stock, representing 4.6% of the class. The filing reports shared voting power and shared dispositive power for all 1,466,506 shares and no sole voting or dispositive power. The issuer is identified as Collegium Pharmaceutical (common stock, $0.001 par). The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Insights

Financial Analyst

TL;DR Institutional ownership of 1,466,506 shares (4.6%) is disclosed with no sole control and a certification of passive, ordinary-course holdings.

Principal Global Investors reports a 4.6% position with shared voting and dispositive authority over the reported shares and explicitly states the holdings are in the ordinary course of business and not intended to influence control. For investors, this is a transparent disclosure of an institutional stake below typical 5% activist thresholds; it documents exposure but does not indicate an immediate change to governance or control dynamics based solely on this filing.

Corporate Governance Expert

TL;DR A sub-5% institutional stake with shared power provides disclosure and monitoring value but does not confer control.

The filing identifies Principal Global Investors as the reporting person with shared voting and dispositive power over 1,466,506 shares (4.6%). The explicit certification that the securities are not held to influence control is material to governance interpretation: the filing documents an ownership level that increases institutional visibility without indicating activism or board influence from the filer itself.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

COLLEGIUM PHARMACEUTICAL, INC

(Name of Issuer)

Common stock, par value $0.001 per share

(Title of Class of Securities)

19459J104

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 19459J104

1

Names of Reporting Persons

PRINCIPAL GLOBAL INVESTORS

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,466,506.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,466,506.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,466,506.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: COLLEGIUM PHARMACEUTICAL, INC
(b)	Address of issuer's principal executive offices: 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MASSACHUSETTS 02072
Item 2.
(a)	Name of person filing: PRINCIPAL GLOBAL INVESTORS
(b)	Address or principal business office or, if none, residence: 711 HIGH STREET DES MOINES, Iowa 50392-0300
(c)	Citizenship: PRINCIPAL GLOBAL INVESTORS - DELAWARE
(d)	Title of class of securities: Common stock, par value $0.001 per share
(e)	CUSIP No.: 19459J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,466,506
(b)	Percent of class: 4.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: PRINCIPAL GLOBAL INVESTORS - 0
	(ii) Shared power to vote or to direct the vote: PRINCIPAL GLOBAL INVESTORS - 1,466,506
	(iii) Sole power to dispose or to direct the disposition of: PRINCIPAL GLOBAL INVESTORS - 0
	(iv) Shared power to dispose or to direct the disposition of: PRINCIPAL GLOBAL INVESTORS - 1,466,506
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PRINCIPAL GLOBAL INVESTORS

Signature:	/s/ J. Markham Penrod
Name/Title:	Chief Compliance Officer - North America, Principal Asset Management
Date:	08/08/2025

FAQ

Who filed the Schedule 13G/A for Collegium Pharmaceutical (COLL)?

Principal Global Investors filed the statement as the reporting person.

How many Collegium (COLL) shares does Principal Global Investors report owning?

The filing reports beneficial ownership of 1,466,506 shares.

What percentage of Collegium stock does the reported stake represent?

The reported position represents 4.6% of Collegium's common stock class.

What voting and dispositive powers does the filer claim?

The filer reports 0 sole voting or dispositive power and shared voting and shared dispositive power over all 1,466,506 shares.

Does the filing indicate the filer intends to influence control of Collegium?

The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.